Advanced Glycation End-Product of Low Density Lipoprotein Activates the Toll-Like 4 Receptor Pathway Implications for Diabetic Atherosclerosis

• Published in: Arteriosclerosis, thrombosis, and vascular biology Vol. 28; no. 12; pp. 2275 - 2281
• Main Authors: Hodgkinson, Conrad P, Laxton, Ross C, Patel, Kunal, Ye, Shu
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Heart Association, Inc 01-12-2008; Lippincott Williams & Wilkins
• Subjects: Animals; Atherosclerosis (general aspects, experimental research); Atherosclerosis - etiology; Atherosclerosis - metabolism; Biological and medical sciences; Blood and lymphatic vessels; Blood. Blood coagulation. Reticuloendothelial system; Cardiology. Vascular system; Cells, Cultured; Diabetic Angiopathies - etiology; Diabetic Angiopathies - metabolism; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Endothelial Cells - drug effects; Endothelial Cells - metabolism; Glycation End Products, Advanced - metabolism; Glycation End Products, Advanced - pharmacology; Humans; Interleukin-6 - biosynthesis; Lipoproteins, LDL - metabolism; Lipoproteins, LDL - pharmacology; Macrophages - drug effects; Macrophages - metabolism; Medical sciences; Mice; Mice, Knockout; NF-kappa B - metabolism; Pharmacology. Drug treatments; Recombinant Proteins - genetics; Recombinant Proteins - metabolism; Serum Albumin, Bovine - metabolism; Serum Albumin, Bovine - pharmacology; Toll-Like Receptor 4 - deficiency; Toll-Like Receptor 4 - genetics; Toll-Like Receptor 4 - metabolism; Transfection; Tumor Necrosis Factor-alpha - biosynthesis; Endocrinopathy; Vascular disease; toll-like receptors; Diabetes mellitus; Atherosclerosis; Cardiovascular disease; Lipoprotein; advanced glycation end-products; diabetes; Glycation
• ISSN: 1079-5642; 1524-4636
• DOI: 10.1161/ATVBAHA.108.175992

OBJECTIVE—Diabetes is a major risk factor for coronary heart disease. Accumulation of advanced glycation end-products (AGEs) attributable to hyperglycemia in diabetics promotes the development of atherosclerosis. However, the underlying mechanisms remain unclear.
METHODS AND RESULTS—The advanced glycation end-product of low-density-lipoprotein (AGE-LDL) induced proinflammatory cytokine production in human coronary artery endothelial cells and human- and mouse-macrophages. AGE-LDL stimulated cytokine synthesis was markedly reduced in mouse macrophages with a TLR4 loss-of-function mutation. Coimmunoprecipitation experiments indicated AGE-LDL interacts with TLR4, RAGE, and CD36. Incubation of cultured macrophages with TLR4, RAGE, or CD36 antibodies inhibited AGE-LDL stimulation of tumor necrosis factor (TNF)α production. A competitive binding inhibitor of TLR4 blocked AGE-LDL binding to the receptor. After transfection of a HEK293 cell system with wild-type TLR4, AGE-LDL activated a signaling pathway including p38α, JNK, and ERK1 kinases and AP1, Elk1, and NF–κB transcription factors; the net result being increased cytokine production. These effects were absent when cells were transfected with empty plasmid. Two common polymorphisms in TLR4, D299G and T399I, reduced the response of TLR4 to lipopolysaccharide (LPS) but had no effect on AGE-LDL signaling.
CONCLUSIONS—These results indicate that AGE-LDL activates a TLR4-mediated signaling pathway, thus inducing proinflammatory cytokine production. This mechanism may partly explain the increased risk of atherosclerosis observed in diabetics.